APA

Bernot K. M., Siebenaler R. F., Whitman S. P., Zorko N. A., Marcucci G. G., Santhanam R., Ahmed E. H., Ngangana M., McConnell K. K., Nemer J. S., Brook D. L., Kulp S. K., Chen C. S., Frankhouser D., Yan P., Bundschuh R., Zhang X., Dorrance A. M., Dickerson K. E., Jarjoura D., Blum W., Marcucci G. & Caligiuri M. A. (20140310). Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia.

Chicago

Bernot K M, Siebenaler R F, Whitman S P, Zorko N A, Marcucci G G, Santhanam R, Ahmed E H, Ngangana M, McConnell K K, Nemer J S, Brook D L, Kulp S K, Chen C S, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance A M, Dickerson K E, Jarjoura D, Blum W, Marcucci G and Caligiuri M A. 20140310. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia.

Harvard

Bernot K. M., Siebenaler R. F., Whitman S. P., Zorko N. A., Marcucci G. G., Santhanam R., Ahmed E. H., Ngangana M., McConnell K. K., Nemer J. S., Brook D. L., Kulp S. K., Chen C. S., Frankhouser D., Yan P., Bundschuh R., Zhang X., Dorrance A. M., Dickerson K. E., Jarjoura D., Blum W., Marcucci G. and Caligiuri M. A. (20140310). Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia.

MLA

Bernot K M, Siebenaler R F, Whitman S P, Zorko N A, Marcucci G G, Santhanam R, Ahmed E H, Ngangana M, McConnell K K, Nemer J S, Brook D L, Kulp S K, Chen C S, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance A M, Dickerson K E, Jarjoura D, Blum W, Marcucci G and Caligiuri M A. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. : Leukemia. 20140310.